ABSTRACT
Conclusion:
In the majority of cases estimated retinal localization detected by PHP was correlated to CNV localization by FFA. PHP seems to be mostly effective for identifying cent-ral macular dysfunction in CNV secondary to AMD.
Results:
Twenty eyes of 15 patients with a mean age of 70.6±7.1 years and a mean visual acuity of 0.3±0.2 were recruited in the study. In 7 eyes classic, in 3 eyes predominantly classic, in 3 eyes minimally classic, in 5 eyes occult CNV were detected by FFA. Only in 2 eyes pigment epithelium detachment (PED) was found. The estimated retinal localization demonstrated in hyperacuity defect map by PHP was found to be correlated with CNV localization by FFA in 18 eyes.
Materials and Methods:
Patients diagnosed to have CNV related to AMD were enrolled in the study. All participants were evaluated by fundus fluorescein angiography (FFA) after a detailed ophthalmic examination. Central 14°x14° visual field were tested PHP (Foresee PHP, Notalvision). Hyperacuity deviation map and hyperacuity defect maps were recorded by PHP Patients having high false positive or false negative ratios were excluded. The correlation bet-ween the localization of CNV detected by FFA and the possible retinal localization determined by PHP was investigated.
Purpose:
To evaluate the efficacy of a new diagnostic tool for the diagnosis of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) known as preferential hyperacuity perimetry (PHP) to detect and localize the lesion.
Keywords:
Age-related macular degeneration, choroidal neovascularization, preferential hyperacuity perimetry
References
1Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): Design implications. AREDS report no. 1. Control Clin Trials 1999;20(6):573-600.
2Erdem Ü, Bayraktar MZ, Uysal Y. Yaşa baglı makula dejenerasyonunda antioksidan tedavinin etkinligi-1. Retina-Vitreus 2004;12:26-29.
3Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
4Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-134.
5Gragoudas ES, Adamis Ap, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition study in ocular eovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. New Eng J Med 2004;351:2805-2816. 6. Emerson MW, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. Intravitreal bevacizumab (Avastin) treatment of age-related macular degeneration. Retina 2007;27:439-444.
6Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for noevascular age-related macular degeneration. N Eng J Med 2006 Oct 5;355(14):1419-1431.
7Submacular Surgery Tr ials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings. SST report no. 13. Ophthalmology 2004;111:1993-2006.
8Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two years results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
9Verteporfin in Photodynamic Therapy Study Group. Verteporfin theraphy of subfoveal choroidal neovascularization in age-related macular degeneration: two-years results of a randomized clinical trial including lesions with occult but no classic neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
10Treatment of Age-Related Macular Degeneration wit Photodynamic Therapy Study Group, Verteporfin in Photodynamic
11Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
12Preferential Hyperacuity Perimetry Study Group. Preferential hyperacuity perimeter (Preview PHP) for detecting choroidal neovascularization study. Ophthalmology 2005;112:1758-1765.
13Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E, Alster Y, Radaeli O, Avni I, Yassur Y. Replacing the amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003;110:966-970.
14Loewenstein A. The significance of early detection of age-related macular degeneration. Richard&Hinda Rosenthal Foundation Lecture, The Macula Society 29th Annual Meeting. Retina 2007;27:873-878.
15Preferential Hyperacuity Perimeter (PHP) Research Group. Results of a multi-center clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005;25:296-303.
16Westheimer G. The spatial sense of the eye. Invest Ophthalmol Vis Sci 1979;18:893-912.
17Enoch JM, Williams RA, Essock EA, Barricks M. Hyperacuity perimetry: assessment of macular function through ocular opacities. Arch Ophthalmol 1984;102:1164-1168.
18Augustin AJ, Offermann JL, Lutz J, Schmidt-Erfurth U, Torambe P. Comparison of the original Amsler grid with the modified Amsler grid. Results for patients with agerelated macular degeneration. Retina 2005;25:443-445.
19Isaac DL, de Avila MP, Cialdini AP. Comparison of the original Amsler grid qith the preferential hyperaucity perimeter for detecting choroidal neovascularization in agerelated macular degeneration. Arq Bras Oftalmol 2007;70:771-776.
20Gilbert CD, Wiesel TN. Receptive field dynamics in adult primary visual cortex. Nature 1992;356:150-152.
21Parkes L, Lund J, Angelucci A, Solomon JA, Morgan M. Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci 2001;4:739-744.
